Pharma company Invivyd, Inc. just announced it is working with the US Food and Drug Administration (FDA) on a pathway to rapid approval for a product it calls an “alternative” to COVID-19 vaccines.

Neal Browning pushed this story back into view with a short social media post. Newsweek said he marked the 6-year anniversary of Moderna's first human trial. He described his "side effects" with ...

Among adolescents and young adults, cTnI levels remain within normal ranges after mRNA-1273 vaccination, with no evidence of increased myocardial injury.

Preliminary analysis showed the 2025-2026 formula of Spikevax generated greater than an 8-fold increase in LP.8.1-neutralizing antibodies across age groups Clinical findings reinforce preclinical data ...

A new study led by the Centenary Institute and the University of Sydney shows that a nasal vaccine could offer powerful protection against COVID-19. It works by stopping infection in the nose before ...

ETHealthworld.com brings latest vaccine hesitancy news, views and updates from all top sources for the Indian Health industry.

Get any of our free daily email newsletters — news headlines, opinion, e-edition, obituaries and more. My wife and I are agreed, news likely to impact us directly at age 86 is the only news to which ...

Add Yahoo as a preferred source to see more of our stories on Google. President Donald Trump speaks with reporters aboard Air Force One after leaving the World Economic Forum in Davos for Washington, ...

Laura holds a Master's in Experimental Neuroscience and a Bachelor's in Biology from Imperial College London. Her areas of expertise include health, medicine, psychology, and neuroscience. Laura holds ...

CAMBRIDGE, MA / ACCESS Newswire / September 16, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced positive preliminary immunogenicity data for the 2025-2026 formula of Spikevax®, which targets the LP ...